Ventajas de la medición de niveles plasmáticos de infliximab en pacientes con enfermedad inflamatoria intestinal / Advantages of level measurement of infliximab in patients with with inflammatory bowel disease
Rev. Hosp. Clin. Univ. Chile
;
27(3): 240-244, 2016.
Artigo
em Espanhol
| LILACS
| ID: biblio-908191
ABSTRACT
Inflammatory bowel disease includes Crohn´s disease, ulcerative colitis and unclassified colitis. Conventional therapies used for treating these diseases are often insufficient orcontraindicated and biological agents have proved to be effective and safe in these cases. Infliximab is a quimeric IgG1 monoclonal anti-tumor necrosis factor antibody that is capableof inducing and mantaining clinical remission in patients with inflammatory bowel disease. Despite its proven efficacy a considerable group of patients lose response requiring changesin therapy. Serum Infliximab trough levels are correlated with clinical response, endoscopic remission and mucosal healing in patients with inflammatory bowel disease. Monitoring and adjusting therapy guided by drug serum levels have proved to be more cost-effective and safer than empiric adjustments. Current international guidelines recommend the measurement of Infliximab trough levels in the global evaluation and management of these patients to improve treatment, avoid adverse events and unnecessary costs.
Texto completo:
DisponíveL
Índice:
LILACS (Américas)
Assunto principal:
Doenças Inflamatórias Intestinais
/
Infliximab
Tipo de estudo:
Guia de Prática Clínica
Limite:
Feminino
/
Humanos
/
Masculino
Idioma:
Espanhol
Revista:
Rev. Hosp. Clin. Univ. Chile
Assunto da revista:
Medicina
Ano de publicação:
2016
Tipo de documento:
Artigo
País de afiliação:
Chile
Instituição/País de afiliação:
Hospital Clínico Universidad de Chile/CL
/
hospital Clínico Universidad de Chile/CL
Similares
MEDLINE
...
LILACS
LIS